Clinical Trial Update: Phase II Study of Range and Schedule of rPA Doses [Phase 2]

View source ↗

Summary

Phase II study evaluating range and scheduling of recombinant protective antigen (rPA) doses for prevention of anthrax; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax

Drugs mentioned

• rPA (recombinant protective antigen (rPA))

Snippet

Sponsor: PharmAthene UK Limited | Conditions: Prevention of Bacillus Anthracis (Anthrax) Infection | Phase 2 | Status: COMPLETED